715 related articles for article (PubMed ID: 28342824)
1. Development of CAR T cells designed to improve antitumor efficacy and safety.
Jaspers JE; Brentjens RJ
Pharmacol Ther; 2017 Oct; 178():83-91. PubMed ID: 28342824
[TBL] [Abstract][Full Text] [Related]
2. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
3. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
Morgan MA; Schambach A
Front Immunol; 2018; 9():2493. PubMed ID: 30420856
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
5. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
6. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
[TBL] [Abstract][Full Text] [Related]
8. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
11. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
12. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
13. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
14. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Li H; Zhao Y
Protein Cell; 2017 Aug; 8(8):573-589. PubMed ID: 28434147
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
Morgan MA; Schambach A
Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
[TBL] [Abstract][Full Text] [Related]
16. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
Yeku OO; Brentjens RJ
Biochem Soc Trans; 2016 Apr; 44(2):412-8. PubMed ID: 27068948
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.
Xu J; Tian K; Zhang H; Li L; Liu H; Liu J; Zhang Q; Zheng J
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1099-1106. PubMed ID: 29048935
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]